Adult T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma | |
---|---|
Human T-cell(normal) | |
Specialty | Oncology, hematology |
Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare
Globally, the retrovirus HTLV-1 is estimated to infect 20 million people per year with the incidence of ATL approximately 0.05 per 100,000 per year with endemic regions such as regions of Japan, as high as 27 per 100,000 per year.[6] However, cases have increased in non-endemic regions with highest incidence of HTLV-1 in southern/northern islands of Japan, Caribbean, Central and South America, intertropical Africa, Romania, northern Iran. ATL normally occurs around the age of 62 years but median age at diagnosis does depend on prevalence of the HTLV-1 infection in the geographic location.[7]
Current treatment regiments for ATL are based on clinical subtype and response to initial therapy. Some therapy modalities for treatment may not available in all countries therefore strategies differ across the world. All patients are referred to clinical trials if available. Beyond clinical trials, treatments are centered on multiagent chemotherapy, zidovudine plus interferon a (AZT/IFN), and allogenic hematopoietic stem cell transplantation (alloHSCT).[6]
Signs and symptoms
ATL is usually a highly aggressive
Infection with HTLV-1, like infection with other
Transmission
Transmission of
Diagnosis
Diagnosis is made based on the combination of clinical features, characteristic morphologic and immunophenotypic changes of malignant cells. As clinical features and prognosis can be diverse, the disease is subtype-classified into four categories according to the Shimoyama classification: acute, lymphoma, chronic, smoldering.[13] Normally, identification of at least 5 percent of tumor cells in peripheral blood and confirmation of human T-lymphotropic virus type-1 are sufficient for diagnosis of acute, chronic, and smoldering types. For the lymphoma type, histopathologic examination by biopsy of lymph nodes may be needed.[14]
Treatment
Treatment options that have been tried include zidovudine and the CHOP regimen.[11] Pralatrexate has also been investigated.[15] Recently, it has been reported that the traditional glucocorticoid-based chemotherapy toward ATL are largely mediated by thioredoxin binding protein-2 (TBP-2/TXNIP/VDUP1), suggesting the potential use of a TBP-2 inducer as a novel therapeutic target.[16][17]
In 2021, mogamulizumab was approved for relapsed/refractor treatment of ATL in Japan.[18]
At a medical conference in December 2013, researchers reported anywhere from 21 to 50% of ATL patients have disease expressing CD30.[19] Although not FDA approved, treatment with CD30-targeting brentuximab vedotin in CD 30+ cases may be beneficial and supported by current NCCN guidelines.[20]
Epidemiology
HTLV-1 infection in the
ATL is relatively uncommon among those infected with
Research
Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation. Pralatrexate is one compound currently under investigations for the treatment of PTCL.[15]
References
- PMID 4544052.
- PMID 301762.
- S2CID 9299403.
- ^ S2CID 30160899.
- ^ S2CID 7824653.
- ^ S2CID 51719877.
- ^ PMID 22738276.
- PMID 22312108.
- PMID 16118323.
- ^ Matsuoka, M; Suzuki, R (2020). "Treatment and prognosis of adult T cell leukemia-lymphoma". UpToDate. Archived from the original on 2012-07-23. Retrieved 27 July 2012.
- ^ PMID 16155611.
- ^ Gotuzzo, E; Verdonck, K (2004). "HTLV-1: CLINICAL IMPACT OF A CHRONIC INFECTION". NCBI. Archived from the original on 2020-02-22. Retrieved 22 July 2013.
- S2CID 40003053.
- PMID 11380402.
- ^ PMID 19389878.
- PMID 21151022.
- PMID 20398702.
- PMID 22686619.
- ^ Campuzano-Zuluaga, G; Pimentel, A; Diaz, L; Chapman-Fredricks, J; and Ramos, J (2013). "CD30 Expression Is Associated With Decreased Survival In Patients With Acute and Unfavorable Chronic Types Of Adult T-Cell Leukemia-Lymphoma" https://ash.confex.com/ash/2013/webprogram/Paper64702.html
- PMID 30657736.
Further reading
- Franchini, Genoveffa; Nicot, Christophe; Johnson, Julie M. (2003). "Seizing of T Cells by Human T-Cell Leukemia/Lymphoma Virus Type 1". In Vande Woude, George F.; Klein, George (eds.). Seizing of T Cells by Human T-Cell Leukemia⧸Lymphoma Virus Type 1. Advances in Cancer Research. Vol. 89. pp. 69–132. PMID 14587871.
- Centers for Disease Control (CDC) (1987). "Adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type I (HTLV-I) infection--North Carolina". Morbidity and Mortality Weekly Report. 36 (49): 804–6, 812. PMID 2891025.
- Genoveffa Franchini's NCI page: Human Retroviral Diseases: Pathogenesis and Prevention
- International Retrovirology Association